AGA临床实践更新:肠-脑互动障碍中慢性胃肠痛的管理
该专家综述总结了肠-脑互动障碍中持续性疼痛的管理方法,聚焦于一线针对内脏原因的治疗失败后的疼痛处理。文章讨论了治疗性医患关系、非药物和药物疗法以及避免阿片类药物的作用,并提出了6条最佳实践建议。
要点
- 建立协作、共情且文化敏感的医患关系是管理持续性疼痛的基础。
- 阿片类药物不应处方用于肠-脑互动障碍的慢性胃肠痛。
- 非药物疗法应常规考虑并尽早引入综合疼痛管理。
核心结论
- 有效管理肠-脑互动障碍的持续性疼痛需要协作、共情且文化敏感的医患关系,并避免使用阿片类药物。
研究设计与样本
- 本综述非正式系统评价,基于文献回顾提供最佳实践建议,未进行正式证据质量评级或推荐强度分级。
主要发现
- 提出了6条最佳实践建议,涵盖医患关系、沟通语言、阿片类药物避免、非药物疗法、优化药物疗法及神经调节剂使用。
关键数值与推荐
- 最佳实践建议1:有效管理持续性疼痛需要协作、共情、文化敏感的医患关系。
- 最佳实践建议2:提供者应掌握关于疼痛发病机制的患者友好语言,并理解疼痛持续的心理背景。
- 最佳实践建议3:阿片类药物不应处方用于肠-脑互动障碍的慢性胃肠痛;若患者已使用,应通过多学科协作负责任地处方直至停用。
- 最佳实践建议4:非药物疗法应常规考虑作为综合疼痛管理的一部分,并理想地尽早引入。
- 最佳实践建议5:提供者应优化已知可调节疼痛的药物治疗,并能区分胃肠痛由内脏因素还是中枢介导因素触发。
临床怎么用
- 临床中应建立良好医患关系,避免阿片类药物,常规考虑非药物疗法,优化药物治疗并合理使用神经调节剂。
局限性
- 本综述非正式系统评价,未进行正式证据质量评级或推荐强度分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: This expert review summarizes approaches to management of pain in disorders of gut-brain interaction. This review focuses specifically on approaches to pain that persist if first-line therapies aimed at addressing visceral causes of pain are unsuccessful. The roles of a therapeutic patient-provider relationship, nonpharmacologic and pharmacologic therapies, and avoidance of opioids are discussed. METHODS: This was not a formal systematic review but was based on a review of the literature to provide best practice advice statements. No formal rating of the quality of evidence or strength of recommendation was performed. BEST PRACTICE ADVICE 1: Effective management of persistent pain in disorders of gut-brain interaction requires a collaborative, empathic, culturally sensitive, patient-provider relationship. BEST PRACTICE ADVICE 2: Providers should master patient-friendly language about the pathogenesis of pain, leveraging advances in neuroscience and behavioral science. Providers also must understand the psychological contexts in which pain is perpetuated. BEST PRACTICE ADVICE 3: Opioids should not be prescribed for chronic gastrointestinal pain because of a disorder of gut-brain interaction. If patients are referred on opioids, these medications should be prescribed responsibly, via multidisciplinary collaboration, until they can be discontinued. BEST PRACTICE ADVICE 4: Nonpharmacologic therapies should be considered routinely as part of comprehensive pain management, and ideally brought up early on in care. BEST PRACTICE ADVICE 5: Providers should optimize medical therapies that are known to modulate pain and be able to differentiate when gastrointestinal pain is triggered by visceral factors vs centrally mediated factors. BEST PRACTICE ADVICE 6: Providers should familiarize themselves with a few effective neuromodulators, knowing the dosing, side effects, and targets of each and be able to explain to the patient why these drugs are used for the management of persistent pain.
引用
- Keefer L, Ko CW, Ford AC, et al. AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. Clin Gastroenterol Hepatol. 2021. PMID: 34229040. doi:10.1016/j.cgh.2021.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。